Epizyme and LLS reach milestone in fight against mixed lineage leukemia
Today the Leukemia & Lymphoma Society (LLS) and biotech Epizyme announced that the two have achieved a pre-clinical milestone in their partnership to develop Epizyme's DOT1L-targeted histone methyltransferase inhibitor (HMTi) for the treatment of mixed lineage leukemia (MLL).
MLL is an acute leukemia that hits people of all ages.
With partial funding from the LLS, Epizyme is working on developing the DOT1L program through Phase 1. According to the partnership agreement, LLS has paid $2.6 million of a potential $7.5 million to fund this program.
Said Richard Winneker, Senior Vice President, Research at LLS, "[We are] committed to finding cures for all blood cancers, including acute leukemias of this type, and Epizyme continues to make rapid progress in developing a DOT1L HMTi as a personalized therapeutic for patients with MLL."
Source: MarketWatch
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
